Invention Grant
- Patent Title: Chimeric molecules providing targeted costimulation for adoptive cell therapy
-
Application No.: US17822251Application Date: 2022-08-25
-
Publication No.: US11697677B2Publication Date: 2023-07-11
- Inventor: John Bridgeman , Robert Hawkins , Ruben Rodriguez , Sujita Sukumaran , Xingliang Zhou , Eric Gschweng
- Applicant: Instil Bio (UK) Limited
- Applicant Address: GB Manchester
- Assignee: INSTIL BIO (UK) LIMITED
- Current Assignee: INSTIL BIO (UK) LIMITED
- Current Assignee Address: GB Manchester
- Agency: Knobbe, Martens, Olson & Bear, LLP
- Main IPC: C07K14/705
- IPC: C07K14/705 ; C07K14/725 ; C07K16/28
Abstract:
The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.
Public/Granted literature
- US20230059511A1 CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY Public/Granted day:2023-02-23
Information query
